Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant [177Lu]Lu-PSMA-I&T radioligand therapy for oligometastatic prostate cancer
2022-004115-92Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Jan 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 PSMA I&T in prostate cancer (PCa), sponsored by Medical University of Vienna. Primary endpoints: Safety and toxicity of neoadjuvant PSMA-RLT plus radical prostatectomy and PSA complete response to PSMA-RLT followed by radical prostatectomy. Started Jan 2023; status: active.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-004115-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-004115-92.